​

Cytokinetics (CYTK) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

CYTK Stock Forecast

Cytokinetics (CYTK) stock forecast, based on 29 Wall Street analysts, predicts a 12-month average price target of $61.00, with a high of $67.00 and a low of $55.00. This represents a 47.99% increase from the last price of $41.22.

$40 $49 $58 $67 $76 $85 High: $67 Avg: $61 Low: $55 Last Closed Price: $41.22

CYTK Stock Rating

Cytokinetics stock's rating consensus is Buy, based on 29 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 26 Buy (89.66%), 3 Hold (10.34%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 29 3 26 0 Strong Sell Sell Hold Buy Strong Buy

CYTK Price Target Upside V Benchmarks

TypeNameUpside
StockCytokinetics47.99%
SectorHealthcare Stocks 30.37%
IndustryBiotech Stocks 73.37%

Price Target Trends

1M3M12M
# Anlaysts1213
Avg Price Target$55.00$61.00$87.15
Last Closing Price$41.22$41.22$41.22
Upside/Downside33.43%47.99%111.43%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 258103--21
Mar, 258103--21
Feb, 25784--19
Jan, 25784--19
Dec, 24774--18
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Apr 24, 2025Gena WangBarclays$55.00$40.3336.37%33.43%
Mar 07, 2025Morgan Stanley$67.00$43.2754.84%62.54%
Oct 17, 2024Joseph PantginisH.C. Wainwright$120.00$55.28117.08%191.12%
Sep 03, 2024Paul ChoiGoldman Sachs$60.00$54.569.97%45.56%
Jun 10, 2024Yasmeen RahimiPiper Sandler$107.00$53.21101.09%159.58%
Jun 04, 2024Mayank MamtaniB.Riley Financial$92.00$48.7088.91%123.19%
May 28, 2024Jason ButlerJMP Securities$78.00$48.3061.49%89.23%
May 23, 2024Joseph PantginisH.C. Wainwright$90.00$48.7184.77%118.34%
May 23, 2024Serge BelangerNeedham$72.00$59.2321.56%74.67%
May 23, 2024Akash TewariJefferies$85.00$59.2343.51%106.21%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Apr 24, 2025BarclaysOverweightOverweightinitialise
Dec 18, 2024RBC CapitalOutperformOutperformhold
Nov 19, 2024Goldman SachsNeutralNeutralhold
Nov 18, 2024H.C. WainwrightBuyBuyhold
Oct 17, 2024H.C. WainwrightBuyBuyhold
Sep 20, 2024H.C. WainwrightBuyBuyhold
Sep 03, 2024Goldman SachsNeutralNeutralhold
Aug 13, 2024Goldman SachsNeutraldowngrade
Jun 10, 2024Piper SandlerOverweightOverweighthold
Jun 04, 2024B. RileyBuyBuyhold

Financial Forecast

EPS Forecast

$-20 $-13 $-6 $1 $8 $15 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-2.54$-3.15$-4.48$-5.45$-5.26----
Avg Forecast$-1.71$-3.26$-4.06$-4.88$-5.24$-5.40$-4.04$-0.26$2.83
High Forecast$0.03$0.05$-0.19$-4.35$-4.55$-3.93$-2.50$0.30$11.50
Low Forecast$-7.76$-14.80$-15.96$-5.34$-5.59$-6.97$-6.50$-1.29$-0.55
Surprise %48.54%-3.37%10.34%11.68%0.38%----

Revenue Forecast

$0 $900M $2B $3B $4B $5B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$55.83M$70.43M$94.59M$7.53M$18.47M----
Avg Forecast$70.03M$20.72M$99.32M$21.85M$3.28M$47.78M$292.97M$720.92M$1.24B
High Forecast$260.65M$77.12M$323.22M$91.92M$14.05M$169.91M$303.62M$757.84M$4.18B
Low Forecast$15.34M$4.54M$26.48M$9.62M$279.05K$4.13M$282.31M$683.99M$101.57M
Surprise %-20.27%239.94%-4.76%-65.53%463.28%----

Net Income Forecast

$-1B $-500M $0 $500M $1B $2B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-164.13M$-242.37M$-402.55M$-526.24M$-589.53M----
Avg Forecast$-100.27M$-181.31M$-178.74M$-526.24M$-489.37M$-632.39M$-497.99M$-47.73M$272.92M
High Forecast$-80.22M$-145.04M$-142.99M$-421.00M$-439.27M$-379.04M$-240.98M$29.04M$1.11B
Low Forecast$-120.32M$-217.57M$-214.49M$-631.49M$-539.46M$-672.43M$-627.51M$-124.50M$-52.90M
Surprise %63.69%33.68%125.22%-20.47%----

CYTK Forecast FAQ

Is Cytokinetics stock a buy?

Cytokinetics stock has a consensus rating of Buy, based on 29 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 26 Buy, 3 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Cytokinetics is a favorable investment for most analysts.

What is Cytokinetics's price target?

Cytokinetics's price target, set by 29 Wall Street analysts, averages $61 over the next 12 months. The price target range spans from $55 at the low end to $67 at the high end, suggesting a potential 47.99% change from the previous closing price of $41.22.

How does Cytokinetics stock forecast compare to its benchmarks?

Cytokinetics's stock forecast shows a 47.99% upside, outperforming the average forecast for the healthcare stocks sector (30.37%) and underperforming the biotech stocks industry (73.37%).

What is the breakdown of analyst ratings for Cytokinetics over the past three months?

  • April 2025: 38.10% Strong Buy, 47.62% Buy, 14.29% Hold, 0% Sell, 0% Strong Sell.
  • March 2025: 38.10% Strong Buy, 47.62% Buy, 14.29% Hold, 0% Sell, 0% Strong Sell.
  • February 2025: 36.84% Strong Buy, 42.11% Buy, 21.05% Hold, 0% Sell, 0% Strong Sell.

What is Cytokinetics’s EPS forecast?

Cytokinetics's average annual EPS forecast for its fiscal year ending in December 2025 is $-5.4, marking a 2.66% increase from the reported $-5.26 in 2024. Estimates for the following years are $-4.04 in 2026, $-0.26 in 2027, and $2.83 in 2028.

What is Cytokinetics’s revenue forecast?

Cytokinetics's average annual revenue forecast for its fiscal year ending in December 2025 is $47.78M, reflecting a 158.65% increase from the reported $18.47M in 2024. The forecast for 2026 is $292.97M, followed by $720.92M for 2027, and $1.24B for 2028.

What is Cytokinetics’s net income forecast?

Cytokinetics's net income forecast for the fiscal year ending in December 2025 stands at $-632M, representing an 7.27% increase from the reported $-590M in 2024. Projections indicate $-498M in 2026, $-47.73M in 2027, and $272.92M in 2028.